Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 188

1.

Heterogeneity and shifts in distribution of muscle weakness in myasthenia gravis.

de Meel RHP, Tannemaat MR, Verschuuren JJGM.

Neuromuscul Disord. 2019 Sep;29(9):664-670. doi: 10.1016/j.nmd.2019.07.006. Epub 2019 Jul 26.

2.

Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature.

de Meel RHP, Raadsheer WF, van Zwet EW, Tannemaat MR, Verschuuren JJGM.

J Neuromuscul Dis. 2019;6(3):369-376. doi: 10.3233/JND-190407.

PMID:
31424417
3.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
4.

Myasthenia gravis.

Gilhus NE, Tzartos S, Evoli A, Palace J, Burns TM, Verschuuren JJGM.

Nat Rev Dis Primers. 2019 May 2;5(1):30. doi: 10.1038/s41572-019-0079-y. Review.

PMID:
31048702
5.

The expanded clinical spectrum of anti-GABABR encephalitis and added value of KCTD16 autoantibodies.

van Coevorden-Hameete MH, de Bruijn MAAM, de Graaff E, Bastiaansen DAEM, Schreurs MWJ, Demmers JAA, Ramberger M, Hulsenboom ESP, Nagtzaam MMP, Boukhrissi S, Veldink JH, Verschuuren JJGM, Hoogenraad CC, Sillevis Smitt PAE, Titulaer MJ.

Brain. 2019 Jun 1;142(6):1631-1643. doi: 10.1093/brain/awz094.

6.

MuSK myasthenia gravis monoclonal antibodies: Valency dictates pathogenicity.

Huijbers MG, Vergoossen DL, Fillié-Grijpma YE, van Es IE, Koning MT, Slot LM, Veelken H, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Neurol Neuroimmunol Neuroinflamm. 2019 Feb 21;6(3):e547. doi: 10.1212/NXI.0000000000000547. eCollection 2019 May.

7.

Respiratory and upper limb function as outcome measures in ambulant and non-ambulant subjects with Duchenne muscular dystrophy: A prospective multicentre study.

Ricotti V, Selby V, Ridout D, Domingos J, Decostre V, Mayhew A, Eagle M, Butler J, Guglieri M, Van der Holst M, Jansen M, Verschuuren JJGM, de Groot IJM, Niks EH, Servais L, Straub V, Voit T, Hogrel JY, Muntoni F.

Neuromuscul Disord. 2019 Apr;29(4):261-268. doi: 10.1016/j.nmd.2019.02.002. Epub 2019 Feb 19.

PMID:
30852071
8.

Efgartigimod improves muscle weakness in a mouse model for muscle-specific kinase myasthenia gravis.

Huijbers MG, Plomp JJ, van Es IE, Fillié-Grijpma YE, Kamar-Al Majidi S, Ulrichts P, de Haard H, Hofman E, van der Maarel SM, Verschuuren JJ.

Exp Neurol. 2019 Jul;317:133-143. doi: 10.1016/j.expneurol.2019.03.001. Epub 2019 Mar 6.

9.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
10.

A prospective, double-blind, randomized, placebo-controlled study on the efficacy and safety of influenza vaccination in myasthenia gravis.

Strijbos E, Tannemaat MR, Alleman I, de Meel RHP, Bakker JA, van Beek R, Kroon FP, Rimmelzwaan GF, Verschuuren JJGM.

Vaccine. 2019 Feb 8;37(7):919-925. doi: 10.1016/j.vaccine.2019.01.007. Epub 2019 Jan 16.

PMID:
30660402
11.

The utility of anti-SOX2 antibodies for cancer prediction in patients with paraneoplastic neurological disorders.

Maddison P, Titulaer MJ, Verschuuren JJ, Gozzard P, Lang B, Irani SR, Sabater L, Graus F, Murray A, Chapman CJ.

J Neuroimmunol. 2019 Jan 15;326:14-18. doi: 10.1016/j.jneuroim.2018.11.003. Epub 2018 Nov 8.

12.

Sensitivity of MG-ADL for generalized weakness in myasthenia gravis.

de Meel RHP, Raadsheer WF, van Zwet EW, Verschuuren JJGM, Tannemaat MR.

Eur J Neurol. 2019 Jun;26(6):947-950. doi: 10.1111/ene.13867. Epub 2018 Dec 17.

13.

Serum Acetylcholine Receptor Antibodies Before the Clinical Onset of Myasthenia Gravis.

Strijbos E, Verschuuren JJGM, Kuks JBM.

J Neuromuscul Dis. 2018;5(2):261-264. doi: 10.3233/JND-180313.

PMID:
29865092
14.

Low dystrophin levels are insufficient to normalize the neuromuscular synaptic abnormalities of mdx mice.

van der Pijl EM, van Putten M, Niks EH, Verschuuren JJGM, Aartsma-Rus A, Plomp JJ.

Neuromuscul Disord. 2018 May;28(5):427-442. doi: 10.1016/j.nmd.2018.02.013. Epub 2018 Mar 6.

15.

Downregulation of miRNA-29, -23 and -21 in urine of Duchenne muscular dystrophy patients.

Catapano F, Domingos J, Perry M, Ricotti V, Phillips L, Servais L, Seferian A, Groot I, Krom YD, Niks EH, Verschuuren JJ, Straub V, Voit T, Morgan J, Muntoni F.

Epigenomics. 2018 Jul;10(7):875-889. doi: 10.2217/epi-2018-0022. Epub 2018 Mar 22.

PMID:
29564913
16.

Author Correction: Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.

Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, T' Hoen PAC, Hendriksen JGM, Aartsma-Rus AM, Verschuuren JJGM, Niks EH, Reinders MJT, Kan HE, Lelieveldt BPF.

Sci Rep. 2018 Mar 1;8(1):4058. doi: 10.1038/s41598-018-22154-7.

17.

Distinct representation of muscle weakness in QMG and MG-ADL.

de Meel RHP, Verschuuren JJGM, Tannemaat MR.

Lancet Neurol. 2018 Mar;17(3):204-205. doi: 10.1016/S1474-4422(18)30037-1. No abstract available.

PMID:
29452679
18.

IgG4-mediated autoimmune diseases: a niche of antibody-mediated disorders.

Huijbers MG, Plomp JJ, van der Maarel SM, Verschuuren JJ.

Ann N Y Acad Sci. 2018 Feb;1413(1):92-103. doi: 10.1111/nyas.13561. Epub 2018 Jan 28. Review.

19.

Passive transfer models of myasthenia gravis with muscle-specific kinase antibodies.

Verschuuren JJGM, Plomp JJ, Burden SJ, Zhang W, Fillié-Grijpma YE, Stienstra-van Es IE, Niks EH, Losen M, van der Maarel SM, Huijbers MG.

Ann N Y Acad Sci. 2018 Feb;1413(1):111-118. doi: 10.1111/nyas.13543. Epub 2018 Jan 21. Review.

PMID:
29356029
20.

Evaluation of serum MMP-9 as predictive biomarker for antisense therapy in Duchenne.

Lourbakos A, Yau N, de Bruijn P, Hiller M, Kozaczynska K, Jean-Baptiste R, Reza M, Wolterbeek R, Koeks Z, Ayoglu B, de Klerk D, Campion G, Zaharieva I, Nadarajah VD, Nilsson P, Al-Khalili Szigyarto C, Muntoni F, Lochmüller H, Verschuuren JJ, Goemans N, Tulinius M, Niks EH, de Kimpe S, Aartsma-Rus A, 't Hoen PAC, Spitali P.

Sci Rep. 2017 Dec 20;7(1):17888. doi: 10.1038/s41598-017-17982-y.

21.

Cytokine Profiling of Serum Allows Monitoring of Disease Progression in Inclusion Body Myositis.

Badrising UA, Tsonaka R, Hiller M, Niks EH, Evangelista T, Lochmüller H, Verschuuren JJ, Aartsma-Rus A, Spitali P.

J Neuromuscul Dis. 2017;4(4):327-335. doi: 10.3233/JND-170234.

PMID:
29172005
22.

Clinical Outcomes in Duchenne Muscular Dystrophy: A Study of 5345 Patients from the TREAT-NMD DMD Global Database.

Koeks Z, Bladen CL, Salgado D, van Zwet E, Pogoryelova O, McMacken G, Monges S, Foncuberta ME, Kekou K, Kosma K, Dawkins H, Lamont L, Bellgard MI, Roy AJ, Chamova T, Guergueltcheva V, Chan S, Korngut L, Campbell C, Dai Y, Wang J, Barišić N, Brabec P, Lähdetie J, Walter MC, Schreiber-Katz O, Karcagi V, Garami M, Herczegfalvi A, Viswanathan V, Bayat F, Buccella F, Ferlini A, Kimura E, van den Bergen JC, Rodrigues M, Roxburgh R, Lusakowska A, Kostera-Pruszczyk A, Santos R, Neagu E, Artemieva S, Rasic VM, Vojinovic D, Posada M, Bloetzer C, Klein A, Díaz-Manera J, Gallardo E, Karaduman AA, Oznur T, Topaloğlu H, El Sherif R, Stringer A, Shatillo AV, Martin AS, Peay HL, Kirschner J, Flanigan KM, Straub V, Bushby K, Béroud C, Verschuuren JJ, Lochmüller H.

J Neuromuscul Dis. 2017;4(4):293-306. doi: 10.3233/JND-170280.

23.

Neuromuscular synapse electrophysiology in myasthenia gravis animal models.

Plomp JJ, Huijbers MGM, Verschuuren JJGM.

Ann N Y Acad Sci. 2018 Jan;1412(1):146-153. doi: 10.1111/nyas.13507. Epub 2017 Oct 25. Review.

PMID:
29068559
24.

A prospective, placebo controlled study on the humoral immune response to and safety of tetanus revaccination in myasthenia gravis.

Strijbos E, Huijbers MG, van Es IE, Alleman I, van Ostaijen-Ten Dam MM, Bakker J, van Zwet EW, Jol-van der Zijde CM, van Tol MD, Verschuuren JJ.

Vaccine. 2017 Nov 1;35(46):6290-6296. doi: 10.1016/j.vaccine.2017.09.078. Epub 2017 Oct 6.

PMID:
28992975
25.

Timing and localization of human dystrophin isoform expression provide insights into the cognitive phenotype of Duchenne muscular dystrophy.

Doorenweerd N, Mahfouz A, van Putten M, Kaliyaperumal R, T' Hoen PAC, Hendriksen JGM, Aartsma-Rus AM, Verschuuren JJGM, Niks EH, Reinders MJT, Kan HE, Lelieveldt BPF.

Sci Rep. 2017 Oct 3;7(1):12575. doi: 10.1038/s41598-017-12981-5. Erratum in: Sci Rep. 2018 Mar 1;8(1):4058.

26.

Antibodies to TRIM46 are associated with paraneoplastic neurological syndromes.

van Coevorden-Hameete MH, van Beuningen SFB, Perrenoud M, Will LM, Hulsenboom E, Demonet JF, Sabater L, Kros JM, Verschuuren JJGM, Titulaer MJ, de Graaff E, Sillevis Smitt PAE, Hoogenraad CC.

Ann Clin Transl Neurol. 2017 Jul 28;4(9):680-686. doi: 10.1002/acn3.396. eCollection 2017 Sep.

27.

Spatially localized phosphorous metabolism of skeletal muscle in Duchenne muscular dystrophy patients: 24-month follow-up.

Hooijmans MT, Doorenweerd N, Baligand C, Verschuuren JJGM, Ronen I, Niks EH, Webb AG, Kan HE.

PLoS One. 2017 Aug 1;12(8):e0182086. doi: 10.1371/journal.pone.0182086. eCollection 2017.

28.

Aggregated N-of-1 trials for unlicensed medicines for small populations: an assessment of a trial with ephedrine for myasthenia gravis.

Weinreich SS, Vrinten C, Kuijpers MR, Lipka AF, Schimmel KJM, van Zwet EW, Gispen-de Wied C, Hekster YA, Verschuuren JJGM, Cornel MC.

Orphanet J Rare Dis. 2017 May 12;12(1):88. doi: 10.1186/s13023-017-0636-y.

29.

Non-uniform muscle fat replacement along the proximodistal axis in Duchenne muscular dystrophy.

Hooijmans MT, Niks EH, Burakiewicz J, Anastasopoulos C, van den Berg SI, van Zwet E, Webb AG, Verschuuren JJGM, Kan HE.

Neuromuscul Disord. 2017 May;27(5):458-464. doi: 10.1016/j.nmd.2017.02.009. Epub 2017 Feb 21.

PMID:
28302391
30.

Translation and validation of the 15-item Myasthenia Gravis Quality of life scale in Dutch.

Strijbos E, Gärtner FR, Verschuuren JJ.

Muscle Nerve. 2018 Feb;57(2):206-211. doi: 10.1002/mus.25641. Epub 2017 May 9.

PMID:
28271514
31.

Proton Magnetic Resonance Spectroscopy Indicates Preserved Cerebral Biochemical Composition in Duchenne Muscular Dystrophy Patients.

Doorenweerd N, Hooijmans M, Schubert SA, Webb AG, Straathof CS, van Zwet EW, van Buchem MA, Verschuuren JJ, Hendriksen JG, Niks EH, Kan HE.

J Neuromuscul Dis. 2017;4(1):53-58. doi: 10.3233/JND-160201.

PMID:
28269793
32.

Improved olefinic fat suppression in skeletal muscle DTI using a magnitude-based dixon method.

Burakiewicz J, Hooijmans MT, Webb AG, Verschuuren JJGM, Niks EH, Kan HE.

Magn Reson Med. 2018 Jan;79(1):152-159. doi: 10.1002/mrm.26655. Epub 2017 Mar 5.

PMID:
28261865
33.

Ephedrine treatment for autoimmune myasthenia gravis.

Lipka AF, Vrinten C, van Zwet EW, Schimmel KJ, Cornel MC, Kuijpers MR, Hekster YA, Weinreich SS, Verschuuren JJ.

Neuromuscul Disord. 2017 Mar;27(3):259-265. doi: 10.1016/j.nmd.2016.11.009. Epub 2016 Nov 18.

34.

Neuromuscular diseases: hope and hurdles in clinical trials.

Verschuuren JJ.

Lancet Neurol. 2017 Jan;16(1):12-13. doi: 10.1016/S1474-4422(16)30335-0. Review. No abstract available.

PMID:
27979339
35.

Decreased cerebral perfusion in Duchenne muscular dystrophy patients.

Doorenweerd N, Dumas EM, Ghariq E, Schmid S, Straathof CS, Roest AA, Wokke BH, van Zwet EW, Webb AG, Hendriksen JG, van Buchem MA, Verschuuren JJ, Asllani I, Niks EH, van Osch MJ, Kan HE.

Neuromuscul Disord. 2017 Jan;27(1):29-37. doi: 10.1016/j.nmd.2016.10.005. Epub 2016 Oct 17.

PMID:
27927595
36.

Elevated phosphodiester and T2 levels can be measured in the absence of fat infiltration in Duchenne muscular dystrophy patients.

Hooijmans MT, Niks EH, Burakiewicz J, Verschuuren JJ, Webb AG, Kan HE.

NMR Biomed. 2017 Jan;30(1). doi: 10.1002/nbm.3667. Epub 2016 Nov 17.

PMID:
27859827
37.

Activity limitations in myasthenia gravis and relation to clinical variables.

De Meel RHP, Lipka AF, Van Der Lende M, Van Zwet EW, Tannemaat MR, Verschuuren JJGM.

Muscle Nerve. 2017 Jul;56(1):64-70. doi: 10.1002/mus.25463. Epub 2016 Dec 2.

PMID:
27859371
38.

Increased risk for clinical onset of myasthenia gravis during the postpartum period.

Boldingh MI, Maniaol AH, Brunborg C, Weedon-Fekjær H, Verschuuren JJ, Tallaksen CM.

Neurology. 2016 Nov 15;87(20):2139-2145. Epub 2016 Oct 21.

39.

Isoaspartylation appears to trigger small cell lung cancer-associated autoimmunity against neuronal protein ELAVL4.

Pulido MA, DerHartunian MK, Qin Z, Chung EM, Kang DS, Woodham AW, Tsou JA, Klooster R, Akbari O, Wang L, Kast WM, Liu SV, Verschuuren JJGM, Aswad DW, Laird-Offringa IA.

J Neuroimmunol. 2016 Oct 15;299:70-78. doi: 10.1016/j.jneuroim.2016.09.002. Epub 2016 Sep 3.

40.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

41.

The epidemiology of neuromuscular disorders: Age at onset and gender in the Netherlands.

Deenen JC, van Doorn PA, Faber CG, van der Kooi AJ, Kuks JB, Notermans NC, Visser LH, Horlings CG, Verschuuren JJ, Verbeek AL, van Engelen BG.

Neuromuscul Disord. 2016 Jul;26(7):447-52. doi: 10.1016/j.nmd.2016.04.011. Epub 2016 Apr 21.

PMID:
27212207
42.

Myasthenia gravis with muscle specific kinase antibodies mimicking amyotrophic lateral sclerosis.

Huijbers MG, Niks EH, Klooster R, de Visser M, Kuks JB, Veldink JH, Klarenbeek P, Van Damme P, de Baets MH, van der Maarel SM, van den Berg LH, Verschuuren JJ.

Neuromuscul Disord. 2016 Jun;26(6):350-3. doi: 10.1016/j.nmd.2016.04.004. Epub 2016 Apr 6.

PMID:
27133662
43.

Characterization of neuromuscular synapse function abnormalities in multiple Duchenne muscular dystrophy mouse models.

van der Pijl EM, van Putten M, Niks EH, Verschuuren JJ, Aartsma-Rus A, Plomp JJ.

Eur J Neurosci. 2016 Jun;43(12):1623-35. doi: 10.1111/ejn.13249. Epub 2016 May 9.

PMID:
27037492
44.

Myasthenia gravis: subgroup classifications - Authors' reply.

Gilhus NE, Verschuuren JJ.

Lancet Neurol. 2016 Apr;15(4):357-8. doi: 10.1016/S1474-4422(16)00035-1. No abstract available.

PMID:
26971656
45.

Longitudinal epitope mapping in MuSK myasthenia gravis: implications for disease severity.

Huijbers MG, Vink AF, Niks EH, Westhuis RH, van Zwet EW, de Meel RH, Rojas-García R, Díaz-Manera J, Kuks JB, Klooster R, Straasheijm K, Evoli A, Illa I, van der Maarel SM, Verschuuren JJ.

J Neuroimmunol. 2016 Feb 15;291:82-8. doi: 10.1016/j.jneuroim.2015.12.016. Epub 2016 Jan 5.

PMID:
26857500
46.

Genome-Wide Association Study of Late-Onset Myasthenia Gravis: Confirmation of TNFRSF11A and Identification of ZBTB10 and Three Distinct HLA Associations.

Seldin MF, Alkhairy OK, Lee AT, Lamb JA, Sussman J, Pirskanen-Matell R, Piehl F, Verschuuren JJGM, Kostera-Pruszczyk A, Szczudlik P, McKee D, Maniaol AH, Harbo HF, Lie BA, Melms A, Garchon HJ, Willcox N, Gregersen PK, Hammarstrom L.

Mol Med. 2016 Mar;21(1):769-781. doi: 10.2119/molmed.2015.00232. Epub 2015 Nov 10.

47.

Evaluation of skeletal muscle DTI in patients with duchenne muscular dystrophy.

Hooijmans MT, Damon BM, Froeling M, Versluis MJ, Burakiewicz J, Verschuuren JJ, Niks EH, Webb AG, Kan HE.

NMR Biomed. 2015 Nov;28(11):1589-97. doi: 10.1002/nbm.3427. Epub 2015 Oct 9.

48.

Myasthenia gravis: subgroup classification and therapeutic strategies.

Gilhus NE, Verschuuren JJ.

Lancet Neurol. 2015 Oct;14(10):1023-36. doi: 10.1016/S1474-4422(15)00145-3. Review.

PMID:
26376969
49.

An up-date on health-related quality of life in myasthenia gravis -results from population based cohorts.

Boldingh MI, Dekker L, Maniaol AH, Brunborg C, Lipka AF, Niks EH, Verschuuren JJ, Tallaksen CM.

Health Qual Life Outcomes. 2015 Aug 1;13:115. doi: 10.1186/s12955-015-0298-1.

50.

An n-of-one RCT for intravenous immunoglobulin G for inflammation in hereditary neuropathy with liability to pressure palsy (HNPP).

Vrinten C, Gu X, Weinreich SS, Schipper MH, Wessels J, Ferrari MD, Hoijtink H, Verschuuren JJ.

J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):790-1. doi: 10.1136/jnnp-2014-309427. Epub 2015 Jul 17. No abstract available.

Supplemental Content

Loading ...
Support Center